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Impact of model calibration on 
cost-effectiveness analysis of 
cervical cancer prevention
David Moriña1, Silvia de Sanjosé2,3 & Mireia Diaz1,4
Markov chain models are commonly used to simulate the natural history of human papillomavirus 
infection and subsequent cervical lesions with the aim of predicting future benefits of health 
interventions. Developing and calibrating these models entails making a number of critical decisions 
that will influence the ability of the model to reflect real conditions and predict future situations. 
Accuracy of selected inputs and calibration procedures are two of the crucial aspects for model 
performance and understanding their influence is essential, especially when involves policy decisions. 
The aim of this work is to assess the health and economic impact on cervical cancer prevention 
strategies currently under discussion according to the most common methods of model calibration 
combined with different accuracy degree of initial inputs. Model results show large differences on the 
goodness of fit and cost-effectiveness outcomes depending on the calibration approach used, and these 
variations may affect health policy decisions. Our findings strengthen the importance of obtaining good 
calibrated probability matrices to get reliable health and cost outcomes, and are directly generalizable 
to any cost-effectiveness analysis based on Markov chain models.
Cost-effectiveness analysis popularity is growing in the last years as an approach for guiding the efficient alloca-
tion of scarce health care resources and has a large impact on the development, implementation, and evaluation 
of health policies. A better understanding of model performance is important to assess the impact on health out-
comes and ensuing policy decisions. Most analyses involve the use of mathematical models to disease simulation 
that synthesize data from various sources. These models are imbued with an appreciable degree of uncertainty, 
at methodological, modeling or structural, and parameterisations level1. Some guidelines on health economic 
evaluations consider pivotal to assess the implications of uncertainty in the results, either through statistical anal-
ysis or through sensitivity analysis2,3. Much has been written in how to handle uncertainty using deterministic 
and probabilistic sensitivity analyses and the implications on the cost-effectiveness analysis4–6. However, mod-
eling uncertainty is often overlooked, although it may have a much greater impact on results than parameter or 
methodological uncertainty3. Calibration methods address this issue connecting parameter inputs, structure, and 
outputs to identify the best fitting set of inputs within the margin of the uncertainty, or multiple sets of values, that 
mimic some specific empirical data. These values are then used to generate health and economic outputs for dif-
ferent interventions that are the basis for performing cost-effectiveness analysis and to provide decision-makers 
with policy-relevant data on the choices to be made. Therefore, appropriate input parameter estimates are critical 
if the model is to produce reliable and accurate results. Input parameters are generally informed by data available 
from published literature, clinical trials and expert opinion. However, results may vary across data sources and, 
on occasion, the data sources may not provide all the required inputs or are inaccurate, and sometimes natural 
history is not delineated in sufficient detail. Therefore, calibration of model inputs to known epidemiological end-
points informed by existing data can be a useful tool to ensure credibility of the results. Commonly used steps in 
the calibration process include identifying calibration targets, selecting measures of goodness-of-fit (GoF), defin-
ing the parameter space, selecting a search strategy, defining convergence thresholds, and specifying a stopping 
rule. Usual calibration targets include overall and disease-specific mortality and incidence rates.
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In the context of cervical cancer, given the multiple prevention strategies available, mathematical models are 
a common tool to address different policy questions depending on the setting. Human papillomavirus (HPV), a 
common sexually transmitted infection, is considered as a necessary cause of cervical cancer. In fact, most men 
and women are infected with HPV at some time in their lives. Although most HPV infections resolve spontane-
ously, some can lead to formation of cervical abnormalities called cervical intraepithelial neoplasia (CIN), which 
can lead to cervical cancer, the second most common cancer in women worldwide7–11. These CIN, or precursor 
cervical lesions, can be further categorized depending on the degree of severity as CIN1 (mild abnormality), 
CIN2 (moderate to marked abnormality) or CIN3 (severe abnormality). Cervical cancer is a highly preventable 
disease by means of screening to find any precancerous lesions so they can be treated or by HPV vaccination to 
prevent infection from some of the most frequent high-risk types. At this time, the optimum prevention strategy 
is probably a combination of both interventions where specific parameters depend on the individual scenario. In 
Spain, cervical cancer prevention is based on opportunistic screening mainly based on cytology and the incorpo-
ration over the past years of an HPV vaccination program in preadolescent girls.
We used a Markov model that simulates the natural history of human papillomavirus (HPV) infection and 
subsequent cervical disease to evaluate different prevention strategies in Spain. The model generates health and 
economic outcomes such as cases averted, life expectancy (LE) from 11 years, reduction in the lifetime risk of CC, 
life years saved, quality-adjusted life years (QALYs), net health benefits, and lifetime costs for each prevention 
strategy. A robust calibration methodology is needed that can address the simultaneous estimations of these out-
comes. The objective of this study is to explore the impact of some calibration approaches with different accuracy 
of initial inputs in terms of relative deviation from recorded Spanish epidemiological targets, in terms of health 
and economic outcomes, and also in the interpretation of cost-effectiveness analysis.
Methods
Model structure. Details of the Markov model structure have been previously described12. In short, a dis-
crete-time, stochastic Markov chain model that simulates the natural history of HPV infection and cervical 
cancer was constructed. The basic model consists of 12 mutually exclusive and collectively exhaustive health 
states (a diagram is available as supplementary material) [healthy, HPV infection, CIN1-3 lesions, International 
Federation of Gynecology and Obstetrics (FIGO) cervical cancer stages, cancer survival, cervical cancer death, 
and death from other causes]. Death states (both from cervical cancer and other causes) reflect country-specific 
female mortality stratified by age. This closed model follows a single cohort of 11-year-old girls until they reach 
the age of 85 years or death using equal 1-year increments, where every woman has her own probability of pro-
gressing, regressing, or remaining at the same health state. All women start model simulations as healthy and can 
move to the HPV-infected state by acquiring the infection with certain probability. If a woman shows clearance 
of the infection, she will regress to the healthy state and then, reinfection is possible. If the infection persists, the 
woman will move into the CIN1 state and may then progress to CIN2 and later to CIN3 and cancer, or can regress 
and show clearance of the infection. Once in the cancer state, a woman may not regress to other health states, and 
instead progresses through the four stages of cancer according to the FIGO classification. A woman may die from 
cervical cancer if she belongs to the cancer stages or may die at any time from other noncervical cancer cause. 
Nonetheless, every woman has a certain probability of developing symptoms and receiving treatment. After treat-
ment, a woman can return to the healthy state –if she belonged to one of the CIN2-3 states– or go to the cancer 
survival state –if she belonged to one of the FIGO states. Yearly regression and progression transition probabilities 
between health states were extracted from a literature review13–17. For each scenario and calibration method, 100 
cohorts consisting of 100,000 women were simulated and a pooled cohort was analysed.
Calibration. The calibration process is used to compare the values obtained from the model with those 
known empirical data to assess accuracy. For that purpose, it is usually calculated a statistical measure of good-
ness of fit that summarizes the discrepancy between observed and predicted values. One of the most frequently 
goodness-of-fit measures is the mean absolute percentage deviation (MAPD) of model-predicted endpoints from 











where esti are the model based estimates of the i-th endpoint and obsi are the data based target values of the i-th 
endpoint. If the importance of the considered outcomes is not uniform, a weighted version of (1) could be used as 
well, as in18. Computing time was also measured for each calibration approach.
The considered calibration methods are among the most used18, including Nelder-Mead algorithm, controlled 
random search (CRS) algorithm, manual calibration and no calibration. A manually calibrated matrix for Spanish 
data was available as it was previously obtained and used to produce the results reported in12. Two non-calibrated 
matrices were built by randomly modifying the manually calibrated matrix. The impossible transitions and 
absorbing states remained impossible and absorbing in the non-calibrated matrices, while all other probabilities 
were randomly generated to be at most 20% or 80% away from the corresponding probability in the manually 
calibrated matrix.
The Nelder-Mead algorithm is a direct-search algorithm based on geometric transformations of a 
non-degenerative simplex –an evolving set of parameter sets that seeks to move toward a better fit with each 
iteration. Advantages of the Nelder-Mead approach include its efficiency when dealing with a large number of 
parameters –which is key in our context–, as it is an heuristic method that works on a geometrical basis and there 
is no need to calculate derivatives of the objective function, so it is relatively easy to implement and use19. The 
controlled random search algorithms are similar to genetic algorithms20, as both start with a random population 
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of points, and randomly evolve these points by heuristic rules. The procedure used in this work is direct (it does 
not involve gradients) and is applicable to constrained optimization21.
All the calibration methods were build using R22, and the developed scripts are available as supplementary 
material. For controlled random search, package nloptr was used23 while base function optim was used for 
Nelder-Mead search algorithm based calibration. In general, we considered the problem of finding the global 
minimum of the function (1).
Prevention strategies. We considered different scenarios of vaccination alone, screening alone and com-
bined vaccination and screening depending on the programme type, the frequency and, the age of starting and 
ending screening. Simulated strategies reflect in the most reliable possible way the current situation in Spain and 
the potential introduction of HPV primary screening. Intervention characteristics are defined hereafter.
No intervention. A reference scenario without vaccination or screening.
Vaccination alone. We assume that preadolescent girls are successfully vaccinated at the age of 12 years with 
three doses of the vaccine against HPV types 16 and 18. The analysis was carried out assuming favorable vaccine 
with 100% efficacy and lifelong duration of vaccine immunity to prevent cervical lesions caused by HPV 16 and 
18 among uninfected women. No cross-protection against other high-risk HPV types was assumed. The uptake 
is set to 70%.
Screening alone. Screening scenarios may differ by screening test (cytology or HPV DNA testing), assuming a 
frequency of 3 years for cytology (3y-cytology) and 5 years for HPV (5y-HPV), targeted ages (25 to 65 years old), 
and switch age from cytology to HPV testing at 35 years old. Screening coverage is set to 70%. On the basis of a 
study carried out in Spain24 and the most up-to-date available information, we assume that the sensitivity and 
specificity of cytology to detect CIN2 is 38.2 and 97.4% respectively. Regarding CIN3, we set the sensitivity and 
specificity of cytology to 52.3 and 97.6%. Primary HPV DNA testing is performed in women older than 35 years 
of age with cytology triage for positive women. For women younger than 35 years of age, cytology is the reference 
test. The sensitivity and specificity of HPV DNA testing to detect CIN2 is 82.4 and 92.4%, respectively; 98 and 
92.3% to detect CIN3 and 90.5 and 91.9% to detect CIN2+ for cytology after a positive HPV test24. Two screening 
scenarios have been defined, an organized framework assuming that all women are screened within the indicated 
period and opportunistic, where all parameters are set as before but women are supposed to be screened with 
different frequency. In the setting for this study, we assume that 15% of women are screened annually, 15% are 
screened each 2 years, 50% are screened each 3 years, 15% are screened each 4 years and 5% are screened each 5 
years.
Combined vaccination and screening. In this scenario, we implement vaccination in girls aged 12 years, followed 
by screening according to the parameters and assumptions described previously for vaccination and screening 
alone. Both organized and opportunistic screening are conducted independently of vaccination status.
Model outcomes. Given an input transition probabilities matrix, the model returns health and economic 
outputs such as the number of clinical procedures (HPV tests and cytologies), HPV prevalence, the number 
and incidence of CIN lesions according to severity, cancer cases and deaths, life expectancy, QALYs and total 
lifetime and per person costs for each considered prevention strategy. In turn, costs are split out in direct medical 
costs (including cost of cytology/HPV collection kit, complementary procedures, follow-up, treatments, staff, 
disposable supplies, laboratory transport, equipment, other supplies, and facilities), and direct non-medical 
costs (including patient transport and cost of patient time). From the information provided by the model, rel-
evant information for scenario comparison as the number of cervical cancer cases averted, cost-effectiveness 
ratios (CERs), and incremental cost-effectiveness ratios (ICERs) respect the no intervention and the previous 
best non-weakly dominated strategy were obtained. For the purpose of comparing the results, percent change of 
CERs with respect to manual calibration and the average percent change and standard deviation of CERs were 
calculated.
The unitary cost per woman of the preventive interventions considered and treatment of premalignant lesions 
and cancer indexed at year 2016 is available as supplementary material. Indirect costs were not taken into account.
To be conservative, the willingness-to-pay threshold is defined at 20,000 €/QALY on the basis of the lowest 
values reported on the latest Spanish and European literature25–27.
All costs and health outcomes reported were discounted at an annual rate of 3%.
Data availability statement. All data generated or analysed during this study are included in this pub-
lished article (and its Supplementary Information files).
Results
Goodness of fit. Results show that when the original input matrix is close to the targeted data, no differ-
ences were observed between Nelder-Mead or controlled random search, therefore not much improvement is 
obtained after using an optimization algorithm. When the input matrix was far from fitting the observed data 
and no calibration process was carried out, the deviation from the target estimates was over 79% for the worst 
matrix and about 20% for the best. For the manually calibrated matrix the deviation was less than 2%, although it 
required more than 40 days of analyst work. Regarding automatically calibrated matrices, the deviation was about 
7% and 5% with computation times of 7.3 hours and 52.3 hours for Nelder-Mead and controlled random search 
algorithms respectively starting with the good matrix, and similar deviation with computation times of 24.9 hours 
and over 100 hours starting with the worst matrix. These results are summarized in Table 1.
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The observed HPV prevalence and CC incidence and the estimated by the model using each of the matrices 
are shown in Fig. 1, showing huge disturbances from targeted values when the input matrix was not calibrated. 
The manually calibrated matrix provides the best fitting to targeted values while non calibrated matrices produced 
the worst results.
Cost-effectiveness outcomes. Regarding the main cost-effectiveness outcomes, the differences in dis-
counted QALYs, discounted costs per person and CERs among the calibration methods can be seen in Table 2. 
The complete table including undiscounted values is provided as supplementary material.
Table 2 shows that the largest differences in most cost-effectiveness outcomes correspond to the non-calibrated 
matrices as well. For instance, taking the manually calibrated matrix outcomes as a reference, the no intervention 
strategy CER for the non calibrated approach differs about 26 to 33% (for the good and bad input matrices respec-
tively), being this difference about 4-5% for Nelder-Mead and CRS algorithms respectively.
Figure 2 shows the percentage change of CERs for each strategy depending on the calibration method and 
input matrix with respect to the manually calibrated matrix and the overall average (solid black line) and stand-
ard deviation (overprinted number) by calibration method. It can be seen that the results that are more similar to 
those obtained using the manually calibrated matrix correspond to Nelder-Mead and CRS calibrated matrices, 
when the input matrix was relatively well calibrated. Taking all prevention strategies into account, the average 
relative change of CER from the manually calibrated matrix outcomes is 16.8%, 8.7%, 4.1%, 4.6%, 3.5% and 3.3% 
for non-calibrated (bad input matrix), non-calibrated (good input matrix), Nelder-Mead (bad input matrix), 
Nelder-Mead (good input matrix), CRS (bad input matrix) and CRS (good input matrix) respectively.
Figure 3 shows the ICERs calculated with respect to the no intervention scenario. It can be seen that ICERs 
present an erratic behavior and that they do not present a similar pattern, either with the order of the strategies 
or in terms of magnitude of the ratios, even the dispersion of the ICERs is different between calibration methods.
The incremental cost-effectiveness analysis comparing the considered prevention strategies depending on 
the calibration approach and input matrix is summarized in Table 3. As with the ICERs respect to no interven-
tion, no clear pattern can be detected among the different calibration approaches although the cost-effectiveness 
Calibration (matrix) MAPD Computing time (h)
No calibration (bad) 79.0% —
No calibration (good) 20.0% —
Manual 2.0% 1,008.0
Nelder-Mead (bad) 7.0% 24.9
Nelder-Mead (good) 6.9% 7.3
CRS (bad) 5.1% 102.0
CRS (good) 4.9% 52.3
Table 1. Mean absolute percentage deviation (MAPD) and computing time in hours by calibration approach 
and input matrix (good and bad input matrices have a deviation about 20% and 80% from targeted values).
Figure 1. Model predicted values for age-specific HPV prevalence and cervical cancer incidence by 
calibration approach and input matrix. NC = No calibration, MC = Manual calibration, NM = Nelder-Mead, 
CRS = Controlled random search.
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Calibration Strategy QALYs LE % of cases averted Cost (€) CER (€/QALY)
NC (bad)
No intervention 29.7356 54.8909 — 107 3.6
Vaccination 29.7418 54.9047 15.1 178 6.0
5y-HPV (org) 29.7597 54.9419 26.0 268 9.0
3y-cytology (org) 29.7593 54.9488 28.1 319 10.7
3y-cytology (op) 29.7574 54.9360 21.4 354 11.9
Vacc. + 5y-HPV (org) 29.7636 54.9491 37.6 326 11.0
Vacc. + 3y-cytology (org) 29.7623 54.9542 39.0 393 13.2
Vacc. + 3y-cytology (op) 29.7604 54.9434 34.0 425 14.3
NC (good)
No intervention 29.8237 54.8996 — 90 3.0
Vaccination 29.8282 54.9129 14.7 162 5.4
5y-HPV (org) 29.8480 54.9501 30.6 249 8.3
3y-cytology (org) 29.8482 54.9544 29.2 309 10.4
3y-cytology (op) 29.8472 54.9468 27.2 337 11.3
Vacc. + 5y-HPV (org) 29.8492 54.9559 41.9 311 10.4
Vacc. + 3y-cytology (org) 29.8495 54.9593 40.8 384 12.9
Vacc. + 3y-cytology (op) 29.8486 54.9521 38.8 413 13.8
MC
No intervention 29.8631 54.9107 — 79 2.7
Vaccination 29.9000 54.9438 44.5 130 4.4
5y-HPV (org) 29.8856 54.9556 31.6 241 8.1
3y-cytology (org) 29.8863 54.9587 30.2 301 10.1
3y-cytology (op) 29.8836 54.9512 27.5 330 11.0
Vacc. + 5y-HPV (org) 29.9128 54.9696 62.4 284 9.5
Vacc. + 3y-cytology (org) 29.9128 54.9714 61.5 361 12.1
Vacc. + 3y-cytology (op) 29.9128 54.9659 60.3 388 13.0
NM (bad)
No intervention 28.5862 54.9172 — 73 2.6
Vaccination 28.7004 54.9265 14.6 149 5.2
5y-HPV (org) 28.6086 54.9579 28.2 234 8.2
3y-cytology (org) 28.6057 54.9609 27.9 283 9.9
3y-cytology (op) 28.6076 54.9538 24.8 312 10.9
Vacc. + 5y-HPV (org) 28.7166 54.9619 38.9 298 10.4
Vacc. + 3y-cytology (org) 28.7162 54.9641 39.1 363 12.6
Vacc. + 3y-cytology (op) 28.7142 54.9584 36.7 390 13.6
NM (good)
No intervention 29.7332 54.9085 — 78 2.6
Vaccination 29.7439 54.9180 14.6 153 5.2
5y-HPV (org) 29.7604 54.9533 30.1 241 8.1
3y-cytology (org) 29.7601 54.9564 28.3 301 10.1
3y-cytology (op) 29.7593 54.9499 26.5 329 11.1
Vacc. + 5y-HPV (org) 29.7685 54.9585 41.1 304 10.2
Vacc. + 3y-cytology (org) 29.7686 54.9615 39.8 377 12.7
Vacc. + 3y-cytology (op) 29.7668 54.9552 38.4 406 13.6
CRS (bad)
No intervention 28.6707 54.9183 — 73 2.5
Vaccination 28.7727 54.9279 14.3 149 5.2
5y-HPV (org) 28.6925 54.9582 27.8 233 8.1
3y-cytology (org) 28.6887 54.9609 27.9 283 9.9
3y-cytology (op) 28.6889 54.9551 24.9 311 10.8
Vacc. + 5y-HPV (org) 28.7885 54.9622 38.9 297 10.3
Vacc. + 3y-cytology (org) 28.7900 54.9648 38.5 362 12.6
Vacc. + 3y-cytology (op) 28.7902 54.9595 36.3 390 13.5
CRS (good)
No intervention 29.7306 54.9109 — 76 2.6
Vaccination 29.7415 54.9209 15.2 151 5.1
5y-HPV (org) 29.7568 54.9552 29.8 238 8.0
3y-cytology (org) 29.7557 54.9575 27.7 299 10.0
3y-cytology (op) 29.7551 54.9513 26.2 326 11.0
Vacc. + 5y-HPV (org) 29.7648 54.9594 40.8 301 10.1
Vacc. + 3y-cytology (org) 29.7642 54.9621 39.2 376 12.6
Vacc. + 3y-cytology (op) 29.7636 54.9560 37.6 404 13.6
Table 2. Cost-effectiveness outcomes by calibration approach and input matrix. LE = Life expectancy, NC = No 
calibration, MC = Manual calibration, NM = Nelder-Mead, CRS = Controlled random search.
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Figure 2. Percent change of CERs respect to manual calibration for each prevention strategy by calibration 
method and input matrix. The average percent change of CERs corresponds to the solid line and the standard 
deviation to the overprinted number. NC = No calibration, MC = Manual calibration, NM = Nelder-Mead, 
CRS = Controlled random search.
Figure 3. Incremental cost-effectiveness ratios with respect to no intervention scenario by calibration approach 
and input matrix. NC = No calibration, MC = Manual calibration, NM = Nelder-Mead, CRS = Controlled 
random search.
analysis is quite uniform in its direction, despite the differences in ICERs magnitude. Three of the considered 
calibration approaches (manual, Nelder-Mead and CRS with the worst input matrix) point to cost-effectiveness 
of vaccination strategy, although the manual calibration double the costs compared to the other approaches. 
For all calibration methods, both opportunistic and organized cytology are strongly dominated (more costly 
and less effective than other strategies) or weakly dominated (with higher ICERs than more effective strategies), 
and the most cost-effective strategy is the combination of vaccination and organized HPV test screening every 
5 years except for no calibration method using the best input matrix. Regarding this strategy, big differences in 
ICERs magnitude compared with the previous best non-dominated strategy can be seen among the considered 
calibration methods, ranging from 7,655 €/QALY to 52,692 €/QALY and being the results obtained through non 
calibrated matrices the ones resulting in greater ICERs. Nelder-Mead and CRS approaches lead to similar ICERs. 
The combination of vaccination and cytology strategies are over the willingness-to-pay threshold in all cases.
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Discussion
Our analyses suggest that important differences in both goodness of fit and cost-effectiveness outcomes are 
found depending on the calibration approach and input matrix. The non calibrated matrices produced HPV 
prevalence and CC incidence curves absolutely far away from the target values, and the better results in most 
cost-effectiveness outcomes, most similar to those obtained by means of the manually calibrated matrix, corre-
spond to the Nelder-Mead and CRS calibrated matrices using reasonable starting points. There is no clear pattern 
for ICERs across the different calibration approaches, probably due to the fact that there is no consistency in 
the direction and proportion of the difference among QALYs and costs. For instance, with bad input matrices, 
Nelder-Mead and CRS show a large decrease in the QALYs while costs remain similar, leading to important dif-
ferences in ICERs. In our case, all calibration methods except the results coming from non calibrated matrices, 
point to the same strategy as the most cost-effective (combination of vaccination and organized screening with 
HPV testing every 5 years), but ICERs values are widely scattered. These variations in certain circumstances 
could involve different policy decisions determined by the ICER threshold selected. Therefore, the importance of 
a reliable calibration process is critical to get trustable cost-effectiveness results that finally provide the decision 
makers with the most accurate information.
Although the best fitting to targeted values was obtained by manual calibration, this approach requires a huge 
amount of time to produce a reasonable approximation. The advantage of this approach is that one could stop the 
calibration process when the desired deviance is obtained. However, very reasonable results can be obtained by 
automated optimization algorithms as Nelder-Mead, controlled random search or genetic algorithms. In our set-
ting, Nelder-Mead algorithm obtained very reasonable results in a relatively short time, especially if the original 
matrix is not dramatically far from the targeted values. By means of CRS algorithm a slightly lower deviation was 
achieved but much more time was needed and the results are very similar to Nelder-Mead algorithm calibrated 
matrices, which seems to be the best alternative in terms of efficiency.
Markov models are useful for modeling complex health interventions and support problems involving policy 
decisions. However, it suffers from the usual limitations of Markov models28. The main limitation of the present 
study might be that it is based only in one matrix for each kind of calibration approach, due to the large com-
puting time of the automated algorithms. Although no significant differences with the present work might be 
expected, it would be interesting to explore thoroughly the performance of the automated methods, specially 
Nelder-Mead algorithm, by means of a set of randomly generated matrices.
The results obtained in our study are similar to those reported in Taylor et al.18, in the sense that a calibration based 
on the Nelder-Mead algorithm or a strategy combining manual calibration and Nelder-Mead algorithm arises as the 
best approaches, being capable of providing accurate results in a reasonable amount of time. However, Taylor et al.18 
focuses on the goodness of fit of the calibration approaches while we highlight the cost-effectiveness analysis point of 
view because the final goal of the calibration process is to use the best possible input for the health decision-making.
This work shows that a thorough verification of the calibration process is essential in a decision-making 
framework, as large differences can be obtained on health benefits and costs among calibration approaches, with 
an unknown impact on cost-effectiveness analyses that might lead to non-optimal decisions.
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Vaccination dom dom 1,372 662 dom 749 dom
5y-HPV (org) 6,665 6,560 dom dom 5,990 dom 6,155
3y-cytology (org) dom dom dom dom dom dom dom
3y-cytology (op) dom dom dom dom dom dom dom
Vacc. + 5y-HPV (org) 14,746 52,692 12,061 9,206 7,655 9,390 7,964
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